Shantel L Duffy1, Jim Lagopoulos2, Nicole Cockayne3, Simon J G Lewis3, Ian B Hickie3, Daniel F Hermens2, Sharon L Naismith3. 1. Healthy Brain Ageing Program, Clinical Research Unit, Brain & Mind Research Institute, University of Sydney, Sydney, New South Wales, Australia; Clinical Research Unit, Brain & Mind Research Institute, University of Sydney, Sydney, New South Wales, Australia. Electronic address: shantel.duffy@sydney.edu.au. 2. Clinical Research Unit, Brain & Mind Research Institute, University of Sydney, Sydney, New South Wales, Australia. 3. Healthy Brain Ageing Program, Clinical Research Unit, Brain & Mind Research Institute, University of Sydney, Sydney, New South Wales, Australia; Clinical Research Unit, Brain & Mind Research Institute, University of Sydney, Sydney, New South Wales, Australia.
Abstract
OBJECTIVES: As life expectancy increases, the need to prevent major health disorders is clear. Depressive symptoms are common in older adults and are associated with cognitive decline and greater risk for transitioning to major depression. Oxidative stress may be implicated in the pathophysiology of major depression and can be measured in vivo using proton magnetic resonance spectroscopy via the neurometabolite glutathione (GSH). Evidence suggests ω-3 fatty acid (FA) supplementation may prevent depression and directly affect GSH concentration. The aim of this study was to examine the effect of ω-3 FA supplementation on in vivo GSH concentration in older adults at risk for depression. METHODS:Fifty-one older adults at risk for depression were randomized to receive either four 1000-mg ω-3 FA supplements daily (containing eicosapentaenoic acid 1200 mg plus docosahexaenoic acid 800 mg) or placebo (four 1000-mg paraffin oil placebo capsules daily) for 12 wk. Participants underwent magnetic resonance spectroscopy, as well as medical, neuropsychological, and self-report assessments at baseline and after 12 wk of supplementation. GSH was measured in the thalamus and calculated as a ratio to creatine. Depressive symptoms were measured using the Patient Health Questionnaire. RESULTS: Compared with the group given the ω-3 FA supplements, the placebo group had greater change in the GSH-to-creatine ratio in the thalamus (t = 2.00; P = 0.049) after the 12 wk intervention. This increase was in turn associated with a worsening of depressive symptoms (r = 0.43; P = 0.043). CONCLUSIONS:Depressive symptom severity in older adults appears to be associated with increased brain levels of GSH, a key marker of oxidative stress. Importantly, ω-3 FA supplementation may attenuate oxidative stress mechanisms, thereby offering benefits for depression prevention.
RCT Entities:
OBJECTIVES: As life expectancy increases, the need to prevent major health disorders is clear. Depressive symptoms are common in older adults and are associated with cognitive decline and greater risk for transitioning to major depression. Oxidative stress may be implicated in the pathophysiology of major depression and can be measured in vivo using proton magnetic resonance spectroscopy via the neurometabolite glutathione (GSH). Evidence suggests ω-3 fatty acid (FA) supplementation may prevent depression and directly affect GSH concentration. The aim of this study was to examine the effect of ω-3 FA supplementation on in vivo GSH concentration in older adults at risk for depression. METHODS: Fifty-one older adults at risk for depression were randomized to receive either four 1000-mg ω-3 FA supplements daily (containing eicosapentaenoic acid 1200 mg plus docosahexaenoic acid 800 mg) or placebo (four 1000-mg paraffin oil placebo capsules daily) for 12 wk. Participants underwent magnetic resonance spectroscopy, as well as medical, neuropsychological, and self-report assessments at baseline and after 12 wk of supplementation. GSH was measured in the thalamus and calculated as a ratio to creatine. Depressive symptoms were measured using the Patient Health Questionnaire. RESULTS: Compared with the group given the ω-3 FA supplements, the placebo group had greater change in the GSH-to-creatine ratio in the thalamus (t = 2.00; P = 0.049) after the 12 wk intervention. This increase was in turn associated with a worsening of depressive symptoms (r = 0.43; P = 0.043). CONCLUSIONS: Depressive symptom severity in older adults appears to be associated with increased brain levels of GSH, a key marker of oxidative stress. Importantly, ω-3 FA supplementation may attenuate oxidative stress mechanisms, thereby offering benefits for depression prevention.
Authors: Shantel L Duffy; Jim Lagopoulos; Zoe Terpening; Simon J G Lewis; Ron Grunstein; Loren Mowszowski; Nathan Cross; Daniel F Hermens; Ian B Hickie; Sharon L Naismith Journal: Sleep Date: 2016-04-01 Impact factor: 5.849
Authors: Daniel F Hermens; Sean N Hatton; Rico S C Lee; Sharon L Naismith; Shantel L Duffy; G Paul Amminger; Manreena Kaur; Elizabeth M Scott; Jim Lagopoulos; Ian B Hickie Journal: Eur Arch Psychiatry Clin Neurosci Date: 2017-03-29 Impact factor: 5.270
Authors: Jay P McLaughlin; Jason J Paris; Dionyssios Mintzopoulos; Kristen A Hymel; Jae K Kim; Thomas J Cirino; Timothy E Gillis; Shainnel O Eans; Gordana D Vitaliano; Jessica M Medina; Richard C Krapf; Heather M Stacy; Marc J Kaufman Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2017-04-20
Authors: Marialaura Simonetto; Marco Infante; Ralph L Sacco; Tatjana Rundek; David Della-Morte Journal: Nutrients Date: 2019-09-23 Impact factor: 5.717